Cancer Virotherapy and Immunotherapy

RAMON ALEMANY

POSTDOCTORAL RESEARCHERS (R2)
  • Marcel Costa Garcia
PREDOCTORAL RESEARCHERS (R1)
  • Martí Farrera Sal
  • Laura Moya Borrego
SCIENTIFIC SUPPORT
  • Rafael Moreno Olié
  • Silvia Torres Manjon
Cancer
Oncobell

Scientific production

8

PAPERS

3 PUBLICATIONS IN FIRST DECILE

7 PUBLICATIONS IN FIRST QUARTILE

Selected publications

  • de Sostoa J, Fajardo CA, Moreno R, Ramos MD, Farrera-Sal M, Alemany R . Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 10.1186/s40425-019-0505-4
  • Moreno R, Fajardo CA, Farrera-Sal M, Perisé-Barrios AJ, Morales-Molina A, Al-Zaher AA, García-Castro J, Alemany R . Enhanced Antitumor Efficacy of Oncolytic Adenovirus-loaded Menstrual Blood-derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells.. MOLECULAR CANCER THERAPEUTICS. 10.1158/1535-7163.MCT-18-0431
  • Barlabé P., Sostoa J., Fajardo C., Alemany R., Moreno R.. Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers. CANCER GENE THERAPY. 10.1038/s41417-019-0110-1
  • Garcia, M; Moreno, R; Gil-Martin, M; Cascallo, M; de Olza, MO; Cuadra, C; Piulats, JM; Navarro, V; Domenech, M; Alemany, R; Salazar, R. A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. HUMAN GENE THERAPY. 10.1089/hum.2018.107

Research highlights

PROJECTS

5 Ongoing projects
1 Started project

 

3 Ongoing clinical trials
2 Started clinical trials

PUBLISHED WORKS

1 thesis

INNOVATION

2 Patents

2 Licenses

1 Spin-off
 

Selected projects

  • Adenovirus oncolíticos protegidos frente an anticuerpos y armados con transgenes para eliminar el estroma y estimular respuestas inmunes antitumorales. (1/1/2018 – 31/12/2020) PI: ALEMANY BONASTRE, RAMON. Funder: MINISTERIO DE EDUCACION Y CIENCIA.
  • MOTRICOLOR (1/1/2016 – 30/9/2019) PI: ALEMANY BONASTRE, RAMON. Funder: VHIO.
  • Estudio de fase I para evaluar la seguridad, la tolerabilidad y la eficacia de vcn-01 en combinación con Durvalumab (MEDI4736) en pacientes con carcinoma de células escamosas de cabeza y cuello recurrente / metastásico. (12/2/2019 – ) PI: ALEMANY BONASTRE, RAMON. Ref: ICO-VCN-H&N-2018.
  • Estudios traslacionales en relación al proyecto: “Phase II trial of Durvalumab (MEDI4736) plus tremelimumab with concurrent radiotherapy in patients with localized muscle invasive bladder cancer treated with a selective bladder preservation approach” (17/1/2019 – ) PI: ALEMANY BONASTRE, RAMON. Ref: CI-001/19.
  • Medició de l’activitat antitumoral de VCN-01 en models ortotòpics TP11 de ratolí (28/2/2017 – 31/12/2020) PI: ALEMANY BONASTRE, RAMON. Ref: C17_002.